Alexza’s Revised Adasuve REMS Borrows From Risk Management Plan For Zyprexa Relprevv
This article was originally published in The Pink Sheet Daily
Executive Summary
A resubmitted Risk Evaluation and Mitigation Strategy that proposes to limit use of inhaled loxapine to health care facilities with ready access to advanced airway support borrows from language in the REMS for Lilly’s long-acting intramuscular injection formulation of olanzapine, Alexza’s CEO says.
You may also be interested in...
Adasuve’s Extensive REMS Proposal Raises Questions About Whether It Could Work In Practice
Patient screening to ensure pulmonary risks are mitigated could be difficult in emergency room settings, advisory committee says about inhaled loxapine formulation.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.